Compare State Street SPDR S&P Biotech ETF (XBI) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Xpeng Inc - ADR — how do they compare? State Street SPDR S&P Biotech ETF trades at $160, while Xpeng Inc - ADR trades at $10.63 (market cap $10.34B). The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| XBI | XPEV | |
|---|---|---|
Sector | Broad Market / Factor | Consumer Cyclical |
52-Week High | $169.55 | $28.07 |
52-Week Low | $93.43 | $10.57 |
Market Cap | — | $10.34B |
Enterprise Value | — | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
XPEV trades at $10.93, down 0.18% for the day, with a bearish technical signal from moving averages. The company reported a net loss of $1.14B in 2025 despite revenue growth to $76.72B, and recent quarterly earnings missed expectations. Positive developments include a $900M robotics unit funding at a $6.3B valuation and new model launches aimed at boosting deliveries.
The outlook remains cautious due to persistent losses and competitive pressures, but analyst consensus is bullish with a $19 price target. Key risks include execution challenges in EV and robotics segments, while institutional interest and AI-driven initiatives offer potential upside if profitability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
